Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 56Genitourinary 20Gastrointestinal 18Breast 15CNS 10Thoracic 8Other solid neoplasm 7Tumor-Agnostic 6Sarcoma 6Head & Neck 4Dermatologic 2Endocrine 1Classical hematology 1

Conditions

Thrombocytopenia 1Recurrence 1Ovarian Neoplasms 1Neutropenia 1Fallopian Tube Neoplasms 1Anemia 1

Interventions

Cyclophosphamide 79fludarabine phosphate 75Busulfan 53Whole-Body Irradiation 51Mycophenolic Acid 50Cyclosporine 47Peripheral Blood Stem Cell Transplantation 46fludarabine 42Antilymphocyte Serum 37Melphalan 36Tacrolimus 35Filgrastim 30Cord Blood Stem Cell Transplantation 27Radiotherapy 23Methotrexate 22Cytarabine 22Methylprednisolone 19Granulocyte Colony-Stimulating Factor 18apixaban 17Thiotepa 17Dalteparin 13thymoglobulin 12Rivaroxaban 12Alemtuzumab 12eltrombopag 11ferric carboxymaltose 10Surveys and Questionnaires 10Etoposide 10Epoetin Alfa 10Cyclosporins 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × niraparib × Classical hematology × Clear all
NCT03891576 2025-01-17

Newton

Mario Negri Institute for Pharmacological Research

Phase 2 Terminated
83 enrolled
Classical hematologyGynecologic

Anemia, Fallopian Tube Neoplasms, Neutropenia, Ovarian Neoplasms, Recurrence, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡